Long term azithromycin in children with cystic fibrosis: A randomised, placebo-controlled crossover trial

Lancet

Volumn 360, Issue 9338, 2002, Pages 978-984

  Equi, A ^a   Balfour Lynn, I M ^a   Bush, A ^a   Rosenthal, M ^a,b  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b SM5 1AA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; INTERLEUKIN 8; LEUKOCYTE ELASTASE;

ADOLESCENT; ADULT; ARTICLE; BACTERIUM; CHILDHOOD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYSTIC FIBROSIS; DISEASE EXACERBATION; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG USE; EAR DISEASE; EXERCISE TEST; EXERCISE TOLERANCE; EXPIRATORY FLOW; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LIVER DISEASE; LIVER FUNCTION TEST; LUNG DISEASE; LUNG INFECTION; MALE; PRIORITY JOURNAL; PURE TONE AUDIOMETRY; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SPUTUM CULTURE; SPUTUM LEVEL; TREATMENT OUTCOME; WELLBEING;

EID: 0037190575     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)11081-6     Document Type: Article

References (25)

1. Khan T.Z., Wagener J.S., Bost T., Martinez J., Accurso F.J., Riches D.W. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med. 151:1995;1075-1082.
2. Armstrong D.S., Grimwood K., Carlin J.B., et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med. 156:1997;1197-1204.
3. Hoiby N. Diffuse panbronchiolitis and cystic fibrosis: East meets West. Thorax. 49:1994;531-532.
4. Nagai H., Shishido H., Yoneda R., Yamaguchi E., Tamura A., Kurashima A. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration. 58:1991;145-149.
5. Kadota J., Sakito O., Kohno S., et al. A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis. Am Rev Respir Dis. 147:1993;153-159.
6. Khair O.A., Devalia J.L., Abdelaziz M.M., Sapsford R.J., Davies R.J. Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8 and sICAM-1 by cultured human bronchial epithelial cells. Eur Respir J. 8:1995;1451-1457.
7. Dupont M.J., Lapointe J.R. Quantitative effect of roxithromycin and rifampicin on mucoid cultures from directly plated sputum of cystic fibrosis patients chronically colonized with Pseudomonas aeruginosa. Drugs Exp Clin Res. 16:1990;597-605.
8. Kobayashi H. Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. Am J Med. 99:1995;26S-30S.
9. Tateda K., Ishii Y., Matsumoto T., et al. Direct evidence for antipseudomonal activity of macrolides: exposure dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin and azithromycin. Antimicrob Agents Chemother. 40:1996;2271-2275.
10. Jaffe A., Bush A. The anti-inflammatory effects of macrolides in lung disease: state of the art. Paediatric Pulmonol. 31:2001;464-473.
11. Jaffe A., Francis J., Rosenthal M., Bush A. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet. 351:1998;420.
12. American Thoracic Society. Standardization of Spirometry 1994 Update. Am J Respir Crit Care Med 1995; 152: 1107-36.
13. Fuchs H.J., Borowitz D.S., Christiansen D.H., et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis: the pulmozyme study group. N Engl J Med. 331:1994;637-642.
14. Balfour-Lynn I.M., Prasad S.A., Laverty A., Whitehead B.F., Dinwiddie R. A step in the right direction: assessing exercise tolerance in cystic fibrosis. Pediatr Pulmonol. 25:1998;278-284.
15. Orenstein D.M., Nixon P.A., Ross E.A., Kaplan R.M. The quality of well being in cystic fibrosis. Chest. 95:1989;344-347.
16. Campbell M.J., Gardner M.J. Calculating confidence intervals for some non-parametric analyses. BMJ. 296:1988;1454-1456.
17. Nickerson B.G., Lemen R.J., Gerder C.B., Wegman M.J., Robertson G. Within subject variability and percent change for significance of spirometry in normal subjects and in patients with cystic fibrosis. Am Rev Respir Dis. 122:1980;859-866.
18. Cooper P.J., Robertson C.F., Hudson I.L., Phelan P.D. Variability of pulmonary function tests in cystic fibrosis. Pediatr Pulmonol. 8:1990;16-22.
19. Shah P.L., Scott S.F., Geddes D.M., Hodson M.E. Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis. Respir Med. 89:1995;499-502.
20. Davies J., Trindale M., Wallis C., Rosenthal M., Crawford O., Bush A. Retrospective review of the effects of rhDNase in children with cystic fibrosis. Pediatr Pulmonol. 23:1997;243-248.
21. Ripoll L., Reinert P., Pepin L.F., Lagrange P.H. Interaction of macrolides with alpha dornase during DNA hydrolysis. J Antimicrob Chemother. 37:1996;987-991.
22. Balfour-Lynn I., Klein N.J., Dinwiddie R. Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis. Arch Dis Child. 77:1997;124-130.
23. Salva P.S., Doyle N.A., Graham L., Eigen H., Doerschuck C.M. TNF-alpha, IL-8, soluble ICAM-1 and neutrophils in sputum of CF patients. Pediatr Pulmonol. 21:1996;11-19.
24. Emre U., Bernius M., Roblin P.M., et al. Chlamydia pneumoniae infection in patients with cystic fibrosis. Clin Infect Dis. 22:1996;819-823.
25. Gant T.W., O'Connor C.K., Corbitt R., Thorgeirsson U., Thorgeirsson S.S. In vivo induction of liver P-glycoprotein expression by xenobiotics in monkeys. Toxicol Appl Pharmacol. 133:1995;269-276.